Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL27955723 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Ornithine Aketoglutarate SCHEMBL361184 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL28321586 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL755884 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Ornithine SCHEMBL361185 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL14656074 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL27858630 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Ornithine SCHEMBL14656075 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL1425215 | 0.94 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL1425217 | 0.94 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12144848-B2 | Arginine depletion therapy for treatment of GAMT deficiency | IMMEDICA PHARMA AB (SE) | 2024-11-19 | — | — | US | claimed |
| US-20240285567-A1 | COMPOSITIONS AND METHODS FOR IMPROVING KIDNEY FUNCTION | CROSS III WILLIAM H (US) | 2024-08-29 | — | — | US | claimed |
| US-20210379167-A1 | Arginine Depletion Therapy For Treatment of GAMT Deficiency | AERASE, INC. (US) | 2021-12-09 | — | — | US | claimed |
| WO-2020081994-A1 | ARGININE DEPLETION THERAPY FOR TREATMENT OF GAMT DEFICIENCY | AERASE, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12144848-B2 | Arginine depletion therapy for treatment of GAMT deficiency | IMMEDICA PHARMA AB (SE) | 2024-11-19 | — | — | US | disclosed |
| US-20240285567-A1 | COMPOSITIONS AND METHODS FOR IMPROVING KIDNEY FUNCTION | CROSS III WILLIAM H (US) | 2024-08-29 | — | — | US | disclosed |
| CN-110314132-B | Ornithine aspartate injection and preparation method thereof | 上海贵之言医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210379167-A1 | Arginine Depletion Therapy For Treatment of GAMT Deficiency | AERASE, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2020081994-A1 | ARGININE DEPLETION THERAPY FOR TREATMENT OF GAMT DEFICIENCY | AERASE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| CN-101843587-B | Preparation method of ornithine aspartate powder injection for injection | HUBEI HOPE PHARMACEUTICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| CN-101843587-A | Preparation method of ornithine aspartate powder injection for injection | HUBEI HOPE PHARMACEUTICAL CO LTD | 2010-09-29 | — | — | CN | disclosed |
| US-5591613-A | ENZYMATIC CONVERSION OF DL-ARGININE IN THE PRESENCE OF AN L-ARGINASE | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5405761-A | Enzymatic conversion of arginine in presence of enzyme L-arginase; neutralization | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |